Problem
The lack of treatment and diagnostic options for patients with neurodegenerative disorders remains a major barrier to effective care for over 57 million individuals in need.
What if...
we could accelerate drug and diagnostic discovery for millions of dementia patients by creating the largest disease-specific proteomics dataset ever assembled?
The Global Neurodegeneration Proteomics Consortium (GNPC) has brought together top dementia researchers to collaborate on proteomic and associated clinical data analysis to understand and transform patient trajectories.
Opportunity
A better understanding of the key drivers of neurodegenerative disorders — including disease mechanisms specific to and shared among these different diseases — to inform better diagnosis and treatment options.
The GNPC’s Harmonized Data Set (HDS)
By uniting diverse data and researchers working on neurodegenerative disorders globally, we seek to contribute to the advancement of the diagnosis and treatment of conditions impacting over 57 million people in need.
To date, the GNPC has gathered over 40,000 patient samples from over 20 international research groups to create our V1 Harmonized Data Set (HDS), comprising nearly 300,000,000 unique protein measurements. The V1 HDS — and subsequent V2 HDS, now in progress — spans multiple neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
This represents the world’s largest protein biomarker discovery effort for neurodegenerative diseases. The GNPC includes proteomics data from some of the largest and most highly characterized clinical cohorts in the world.
Our preliminary research efforts are using both longitudinal and cross-sectional data and focus on the insights gained from protein and proteogenomic analyses. Our goal is to better understand mechanisms specific to a single disease as well as those shared across multiple neurodegenerative disorders.
Consortium members and partners
GNPC members include top research institutions from around the world working across multiple neurodegenerative disorders. The consortium is also a first-of-its-kind public-private partnership that brings together academic, governmental and industry researchers to collaborate. Our functional partners the Alzheimer’s Disease Data Initiative (AD Data Initiative), MMS, Olink, and SomaLogic contribute their services to support our rigorous attention to privacy and security.
Core funding partners
Data platform
Additional funders
Program partners
Cohorts
Contact Us
Please contact info@neuroproteome.org with inquiries about joining the Global Neurodegeneration Proteomics Consortium (GNPC) or questions about accessing the resulting data.
